A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide

European Journal of Medical Research

Volumn 14, Issue 1, 2009, Pages 44-46

  Feiterna Sperling, Cornelia ^a   Walter, H ^b   Wahn, V ^a   Kleinkauf, N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Enfuvirtide; Highly active antiretroviral therapy; HIV 1 infection; Multidrug resistant HIV 1; Tipranavir oral solution

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE REACTION; LIVER FUNCTION TEST; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; MEDICAL DECISION MAKING; MULTIDRUG RESISTANCE; NAUSEA; PATIENT COMPLIANCE; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; PEPTIDE FRAGMENTS; PYRIDINES; PYRONES; REMISSION INDUCTION; RITONAVIR; TREATMENT OUTCOME;

EID: 59949101994     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Boehringer Ingelheim International GmbH, Aptivus® (tipranavir) Capsules - Summary of Product Characteristics (SPC), 2007
2. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wohrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007; 369: 1169-78.
3. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS. 2007; 21: 721-32.
4. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, Song LY, Dankner WM, Oleske JM. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001; 345:1522-8.
5. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006; 368: 466-75.
6. Martin S, Elliott-DeSorbo DK, Wolters PL, Toledo-Tamula MA, Roby G, Zeichner S, Wood LV. Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect Dis J. 2007; 26: 61-7.
7. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338: 853-860.
8. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed on March 29, 2008.
9. Sabo JP, Cahn P, Della Negra M, Castelli-Gattinara G, Fortuny C, Yogev R, Salazar J, Yong CL, Milk J, Jelaska A. Population pharmacokinetic assessment of systemic steady-state tipranavir concentrations for HIV+ pediatric patients administered tipranavir/ritonavir: BI 1182.14 and PACTG 1051 study team. 13th Conference on Retroviruses and Opportunistic Infections. Denver, USA 2006; Abstract no. R-136.
10. Salazar JC, Cahn P, Yogev R, Della Negra M, Castelli-Gattinara G, Fortuny C, Flynn PM, Giaquinto C, Ruan PK, Smith ME, Mild J, Jelaska A, Yogev R, Caparelli T, Fenton T, Mikl J, Jelaska A, for the PACTG 1051/BI Study Team. Efficacy, and safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS. 2009; 22: 1789-1798.
11. Scherer J, Boucher CA, Baxter JD, Shapiro JM, Kohlbrenner VM, Hall DB. Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score. 11th European AIDS Conference. Madrid, Spain, 24-27 October 2007; Abstract no. P3.4/07.
12. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999; 18: 682-9.
13. Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, Bertasso A. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J; 2007; 26: 799-805.
14. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 28, 2008; 1-134. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidefines.pdf. Accessed on March 29, 2008.